Here are the 8-K filings from Faeth Therapeutics, Inc. (FTH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow FTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTH filings page.
Faeth Therapeutics, Inc. reported a net loss of $20.398 million for the quarter ended September 30, 2026, compared with $4.569 million a year earlier. Research and development expense was $11.736 million, versus $2.536 million. As of September 30, 2026, cash and cash equivalents were $14.180 million and marketable securities were $160.615 million.
The company said PK/PD analysis informed the PIKTOR dose in its Phase 2 PIK-201 trial, and PIKTOR plus paclitaxel received Fast Track designation for biomarker-selected advanced endometrial cancer. Topline PIK-201 data are anticipated by year-end 2026; initial safety and efficacy data from the PIK-101 breast cancer trial are anticipated in 2027.
Faeth Therapeutics, Inc. (FTH) increased its board from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director, effective immediately on October 23, 2026. He will serve until the 2027 annual meeting of stockholders and until a successor is duly elected and qualified, or his earlier death, resignation or removal. Schayowitz has served as Executive Vice President and Head of Research and Development at Zymeworks since April 2026 and previously held oncology development leadership roles at Pfizer Oncology and Tesaro. His appointment includes a cash retainer and an initial option to purchase 25,000 common shares, with an exercise price equal to the closing price of the common stock on the grant date. The board cited his oncology drug development, clinical and regulatory strategy, and commercialization experience in determining his qualifications.
Faeth Therapeutics, Inc. (FTH) reports that its Board of Directors increased in size from five to six members and appointed co‑founder and cancer biologist Karen Vousden, Ph.D. as a Class II director, effective September 11, 2026. Her term runs until the 2029 annual meeting of stockholders, and she was also named to the Board’s Compensation Committee. In connection with her appointment, Dr. Vousden will receive standard non‑employee director cash compensation and an initial equity award under the 2026 Equity Incentive Plan consisting of an option to purchase 25,000 shares of common stock at the closing market price on the grant date, vesting in equal monthly installments over three years and fully vesting upon a Change in Control, subject to continued service.
Faeth Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and provided clinical and corporate updates. The company highlighted its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing, which it says provides capital to advance its multi-node inhibitor PIKTOR across multiple cancers.
For the quarter, total operating expenses were $18,385 (in thousands), up from $5,206 (in thousands) a year earlier, driven by research and development of $9,180 (in thousands) and general and administrative expenses of $9,205 (in thousands). Net loss was $16,007 (in thousands), compared with $4,936 (in thousands), or $2.84 net loss per share versus $3.91. Cash and cash equivalents were $26,903 (in thousands) and marketable securities were $159,538 (in thousands) as of June 30, 2026.
Operationally, Faeth reported that topline results from its Phase 2 PIK-201 trial in advanced endometrial cancer are on track for year-end 2026, and that the first patient was dosed in its Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026, with initial data anticipated in 2027.
Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants under its 2026 Equity Incentive Plan for employees who were employed as of February 19, 2026, including key executives.
The Chief Executive Officer received options for 398,018 shares, the General Counsel 84,766 shares and the Senior Vice President, Finance 30,824 shares. Each option has an exercise price equal to the closing price of the common stock on the grant date and vests in a single tranche only after a Stock Price Hurdle of $70.00 per share is achieved during a Performance Period that ends on the fourth anniversary of the grant date and at least one year has elapsed, subject to continued service. Unvested options are forfeited if the hurdle is not met or service ends, while a qualifying change in control with per-share consideration of at least $70.00 accelerates vesting.